Goldman Sachs’s 9 Meters Biopharma NMTR Stock Holding History

Goldman Sachs’s Portfolio NMTR Stock Details NMTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-3,817	Closed	-$16K	–	6393
2022 Q3	$16K	Sell	3,817 -234	-6%	-$1.16K	﹤0.01%	5975
2022 Q2	$21K	Buy	4,051 +44	+1%	+$415	﹤0.01%	6166
2022 Q1	$48K	Sell	4,007 -2,242	-36%	-$30.6K	﹤0.01%	6279
2021 Q4	$122K	Sell	6,249 -699	-10%	-$15.6K	﹤0.01%	6082
2021 Q3	$181K	Buy	+6,948	New	+$164K	﹤0.01%	5760
2021 Q2	–	Sell	-4,410	Closed	-$103K	–	6635
2021 Q1	$103K	Buy	+4,410	New	+$136K	﹤0.01%	5837
2019 Q1	–	Sell	-540	Closed	-$25K	–	5536
2018 Q4	$25K	Buy	+540	New	+$40K	﹤0.01%	5138
2018 Q2	–	Sell	-6,426	Closed	-$3.52M	–	6118
2018 Q1	$3.52M	Buy	+6,426	New	+$1.25M	﹤0.01%	3171
2017 Q1	–	Sell	-81	Closed	-$28K	–	7072
2016 Q4	$28K	Sell	81 -20	-20%	-$5.8K	﹤0.01%	6554
2016 Q3	$34K	Buy	+101	New	+$55.9K	﹤0.01%	6606

Other funds holding NMTR

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

ODFS

O'Donnell Financial Services San Rafael, California $290M AUM 15.6% 1-Year Est. Return

Goldman Sachs's NMTR Position: Q4 2022 in Review

Goldman Sachs sold out of 9 Meters Biopharma (NMTR) in Q4 2022, closing a stake of 3,817 shares — an estimated $16K sold.

Goldman Sachs first reported a position in NMTR in Q3 2016 and held it in 10 quarters. The position peaked at $3.52M in Q1 2018. 42 funds tracked by Wall St. Rank hold NMTR as of Q4 2022.

Goldman Sachs reported no remaining 9 Meters Biopharma position as of Q4 2022 after selling out during the quarter.
Goldman Sachs sold 3,817 9 Meters Biopharma shares in Q4 2022, an estimated $16K.
Goldman Sachs first reported a position in 9 Meters Biopharma in Q3 2016 and held it in 10 quarters.
Goldman Sachs's 9 Meters Biopharma position peaked at $3.52M in Q1 2018.
42 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q4 2022.

Based on Goldman Sachs's 13F filing for Q4 2022, filed 13 Feb 2023.